These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
135 related articles for article (PubMed ID: 2679374)
1. Pefloxacin versus ceftazidime in the treatment of a variety of gram-negative-bacterial infections. Giamarellou H; Perdikaris G; Galanakis N; Davoulos G; Mandragos K; Sfikakis P Antimicrob Agents Chemother; 1989 Aug; 33(8):1362-7. PubMed ID: 2679374 [TBL] [Abstract][Full Text] [Related]
2. Pefloxacin versus ceftazidime in therapy of soft tissue infections in compromised patients. Segev S; Rosen N; Pitlik SD; Block C; Rubinstein E J Antimicrob Chemother; 1990 Oct; 26 Suppl B():193-8. PubMed ID: 2258349 [TBL] [Abstract][Full Text] [Related]
3. Comparison of pefloxacin with ceftazidime in severe bronchopulmonary infections. Vanderdonckt J J Antimicrob Chemother; 1990 Oct; 26 Suppl B():111-6. PubMed ID: 2258338 [TBL] [Abstract][Full Text] [Related]
4. [Controlled randomized prospective study of a ceftazidime-pefloxacin combination versus a ceftazidime-amikacin combination in the empirical treatment of nosocomial pneumonias and septicemias of resuscitation. Preliminary results]. Mouton Y; Beuscart C; Leroy O; Pappo M; Drugeon H Presse Med; 1988 Oct; 17(37):1928-32. PubMed ID: 2973588 [TBL] [Abstract][Full Text] [Related]
7. Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli. Zhanel GG; Golden AR; Zelenitsky S; Wiebe K; Lawrence CK; Adam HJ; Idowu T; Domalaon R; Schweizer F; Zhanel MA; Lagacé-Wiens PRS; Walkty AJ; Noreddin A; Lynch Iii JP; Karlowsky JA Drugs; 2019 Feb; 79(3):271-289. PubMed ID: 30712199 [TBL] [Abstract][Full Text] [Related]
8. Double-blind, prospective, multicenter trial comparing ceftazidime with moxalactam in the treatment of serious gram-negative infections. Joshi M; Anthony WC; Tenney JH; Drusano GL; Caplan ES; Standiford HC; Henson A; Warren JW Antimicrob Agents Chemother; 1986 Jul; 30(1):90-5. PubMed ID: 3530128 [TBL] [Abstract][Full Text] [Related]
9. Ceftazidime-avibactam or best available therapy in patients with ceftazidime-resistant Enterobacteriaceae and Pseudomonas aeruginosa complicated urinary tract infections or complicated intra-abdominal infections (REPRISE): a randomised, pathogen-directed, phase 3 study. Carmeli Y; Armstrong J; Laud PJ; Newell P; Stone G; Wardman A; Gasink LB Lancet Infect Dis; 2016 Jun; 16(6):661-673. PubMed ID: 27107460 [TBL] [Abstract][Full Text] [Related]
10. [Prospective randomized controlled study of a ceftazidime and pefloxacin combination versus a ceftazidime and amikacin combination in the empirical treatment of pneumonia and nosocomial septicemia at intensive care units]. Beuscart C; Leroy O; Mouton Y; Pappo M; Drugeon H Pathol Biol (Paris); 1989 May; 37(5):496-9. PubMed ID: 2674875 [TBL] [Abstract][Full Text] [Related]
11. Intravenous ciprofloxacin and ceftazidime in serious infections. A prospective, controlled clinical trial with third-party blinding. Sifuentes-Osornio J; Macías A; Amieva RI; Ramos A; Ruiz-Palacios GM Am J Med; 1989 Nov; 87(5A):202S-205S. PubMed ID: 2686425 [TBL] [Abstract][Full Text] [Related]
12. Development of beta-lactam resistance and increased quinolone MICs during therapy of experimental Pseudomonas aeruginosa endocarditis. Bayer AS; Hirano L; Yih J Antimicrob Agents Chemother; 1988 Feb; 32(2):231-5. PubMed ID: 3129985 [TBL] [Abstract][Full Text] [Related]
13. Intravenous ciprofloxacin or ceftazidime in selected infections. A prospective, randomized, controlled study. Villavicencio J; Asensio de Fernandez ME; Ramirez CA Am J Med; 1989 Nov; 87(5A):191S-194S. PubMed ID: 2686422 [TBL] [Abstract][Full Text] [Related]
14. Prospective, randomized comparison of sequential intravenous followed by oral ciprofloxacin with intravenous ceftazidime in the treatment of serious infections. Peacock JE; Pegram PS; Weber SF; Leone PA Am J Med; 1989 Nov; 87(5A):185S-190S. PubMed ID: 2686421 [TBL] [Abstract][Full Text] [Related]
15. International comparative study of cefepime and ceftazidime in the treatment of serious bacterial infections. Hoepelman AI; Kieft H; Aoun M; Kosmidis J; Strand T; Verhoef J; Gillespie SH; Riddell J; Varghese G; Meunier F J Antimicrob Chemother; 1993 Nov; 32 Suppl B():175-86. PubMed ID: 8150761 [TBL] [Abstract][Full Text] [Related]
16. Pefloxacin versus imipenem in the therapy of nosocomial lung infections of intensive care unit patients. Giamarellou H; Mandragos K; Bechrakis P; Pigas K; Bilalis D; Sfikakis P J Antimicrob Chemother; 1990 Oct; 26 Suppl B():117-27. PubMed ID: 2258339 [TBL] [Abstract][Full Text] [Related]
17. Pefloxacin treatment of meningitis caused by gram-negative bacteria. Segev S; Barzilai A; Rosen N; Joseph G; Rubinstein E Arch Intern Med; 1989 Jun; 149(6):1314-6. PubMed ID: 2730249 [TBL] [Abstract][Full Text] [Related]
18. Evaluation of pefloxacin, ofloxacin and ciprofloxacin in the treatment of thirty-nine cases of chronic osteomyelitis. Dellamonica P; Bernard E; Etesse H; Garraffo R; Drugeon HB Eur J Clin Microbiol Infect Dis; 1989 Dec; 8(12):1024-30. PubMed ID: 2515961 [TBL] [Abstract][Full Text] [Related]
20. Intravenous/oral ciprofloxacin versus ceftazidime in the treatment of serious infections. Fass RJ; Plouffe JF; Russell JA Am J Med; 1989 Nov; 87(5A):164S-168S. PubMed ID: 2589361 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]